Some believe that all DLBCL should be tested for MYC, BCL2 and BCL6 rearrangements, whereas others would restrict this, to cases with a GCB phenotype and/or high-grade morphology or to cases with >40% MYC-positive cells by immunophenotype [1]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.